PDF(Pubmed)
Abstract：
Fluctuating weakness affecting the ocular, bulbar, and/or appendicular muscles is characteristic of myasthenia gravis. Autoimmune components and certain drugs have been implicated in the pathophysiology of this disease. I report a case of chronic migraine in which the patient developed symptoms of myasthenia gravis after using galcanezumab, the recently approved anti-calcitonin gene-related peptide (anti-CGRP). This case shows that anti-CGRP medications could affect the neuromuscular junction and cause such symptoms. Moreover, this case illustrates the clinical approach and management of such a presentation.
摘要：
影响眼部的波动无力，球杆,和/或阑尾肌是重症肌无力的特征。自身免疫成分和某些药物与该疾病的病理生理学有关。我报告了一例慢性偏头痛，其中患者在使用galcanezumab后出现重症肌无力症状，最近批准的抗降钙素基因相关肽（抗CGRP）。这种情况表明，抗CGRP药物可能会影响神经肌肉接头并引起此类症状。此外，该病例说明了这种表现的临床方法和管理。
